Development of 166Ho-Ho, Fe-Hydroxide (HFH) and 166Ho-Hydroxyapatite (HA) for Radioembolization Therapy of Liver Malignancies

The therapeutic radionuclide Ho-166 was produced in the Austrian Research Reactor Seibersdorf. Two potential radiopharmaceuticals, 166Ho-Ho, Fe-Hydroxide (HFH) and 166Ho-Hydroxyapatite (HA) designed for radioembolization therapy of liver malignancies were developed and investigated including biodistribution studies in rabbits. Both kinds of labeled particles were applied via the portal vein and showed a high retention of the Ho-166 in the liver after 4 days.